Efavirenz – 50 mg

Brand:
Cayman
CAS:
154598-52-4
Storage:
-20
UN-No:
De Minimis - 3077 / 9

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to wild-type and mutant HIV-1 RTs (Kis = 2.93 and 3.85-56.5 nM, respectively).{42187} It inhibits wild-type and mutant HIV-1 viral replication in MT-4 human T lymphoid cells (IC95s = 1.5-1,500 nM). Efavirenz also prevents RNA plus-strand initiation with an IC50 value of 17 nM.{22819} In vivo, efavirenz reduces HIV-1 cDNA in spleen of HIV-1-challenged HIV-susceptible transgenic rats.{42188} Formulations containing efavirenz have been used in combination therapy for the treatment of HIV-1.{22821,22820}  

 

SKU: - Category:

Description

An NNRTI (Kis = 2.93 and 3.85-56.5 nM for wild-type and mutant HIV-1 RTs, respectively); inhibits wild-type and mutant HIV-1 viral replication in MT-4 human T lymphoid cells (IC95s = 1.5-1,500 nM); prevents RNA plus-strand initiation (IC50 = 17 nM); reduces HIV-1 cDNA in spleen of HIV-1-challenged HIV-susceptible transgenic rats,


Formal name: (4S)-6-chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one

Synonyms:  DMP 266|EFV|L-743,726

Molecular weight: 315.7

CAS: 154598-52-4

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Antivirals|Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)||Product Type|Biochemicals|Small Molecule Inhibitors|Reverse Transcriptases||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Viral Diseases|HIV & AIDS